View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2018	Nov. 09, 2018
Document Information [Line Items]
Entity Registrant Name	ATOSSA GENETICS INC
Entity Central Index Key	0001488039
Trading Symbol	atos
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		5,646,552
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 12,935,587	$ 7,217,469
Restricted cash	55,000	55,000
Prepaid expenses	290,331	250,944
Research and development tax rebate receivable	480,495	358,277
Other current assets	161,530	16,344
Total current assets	13,922,943	7,898,034
Furniture and equipment, net	57,804	11,467
Intangible assets, net	55,107	75,686
Other assets	88,518	178,907
Total Assets	14,124,372	8,164,094
Current liabilities
Accounts payable	550,704	334,901
Accrued expenses	51,673	90,105
Payroll liabilities	706,150	784,867
Stock-based compensation liability	2,180,659
Other current liabilities	66,077	15,534
Total Current Liabilities	3,555,263	1,225,407
Commitments and contingencies (note 11)
Stockholders' equity
Preferred stock - $0.001 par value; 10,000,000 shares authorized, consisting of Series A convertible preferred stock- $0.001 par value; 4,000 shares authorized, and 0 shares outstanding as of September 30, 2018 and December 31, 2017; Series B convertible preferred stock- $0.001 par value; 25,000 and 0 shares authorized, and 3,517 and 0 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively	4
Additional paid-in capital- Series B convertible preferred stock	3,516,996
Common stock - $0.18 par value; 175,000,000 shares authorized, and 5,523,255 and 2,651,952 shares issued and outstanding, as of September 30, 2018 and December 31, 2017, respectively	994,175	477,342
Additional paid-in capital	80,811,088	71,887,674
Accumulated deficit	(74,753,154)	(65,426,329)
Total Stockholders' Equity	10,569,109	6,938,687
Total Liabilities and Stockholders' Equity	$ 14,124,372	$ 8,164,094

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.18	$ 0.18
Common stock, authorized (in shares)	175,000,000	175,000,000
Common stock, issued (in shares)	5,523,255	2,651,952
Common stock, outstanding (in shares)	5,523,255	2,651,952
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	4,000	4,000
Preferred stock, outstanding (in shares)	0	0
Preferred stock, issued (in shares)	0
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	25,000	0
Preferred stock, outstanding (in shares)	3,517	0
Preferred stock, issued (in shares)	3,517	0

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Operating Expenses
Research and development	$ 1,421,851	$ 742,450	$ 3,360,563	$ 2,110,846
General and administrative	1,888,119	1,313,477	5,966,504	3,544,935
Total operating expenses	3,309,970	2,055,927	9,327,067	5,655,781
Operating loss	(3,309,970)	(2,055,927)	(9,327,067)	(5,655,781)
Change in fair value of common stock warrants		(128,300)		(280,747)
Warrant financing expense				(192,817)
Other income (expense)	104	(283)	242	(208)
Loss before income taxes	(3,309,866)	(2,184,510)	(9,326,825)	(6,129,553)
Income taxes
Net loss	(3,309,866)	(2,184,510)	(9,326,825)	(6,129,553)
Deemed dividend attributable to preferred stock			(11,479,308)	(2,568,132)
Net loss applicable to common shareholders	$ (3,309,866)	$ (2,184,510)	$ (20,806,133)	$ (8,697,685)
Loss per common share -basic and diluted (in dollars per share)	$ (0.64)	$ (2.11)	$ (5.71)	$ (13.23)
Weighted average shares outstanding - basic and diluted (in shares)	5,183,492	1,034,262	3,645,682	657,184

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - 9 months ended Sep. 30, 2018 - USD ($)	Preferred Stock [Member]	Additional Paid in Capital, Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid in Capital, Common Stock [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017			2,651,952
Balance at Dec. 31, 2017			$ 477,342	$ 71,887,674	$ (65,426,329)	$ 6,938,687
Issuance of Series B convertible preferred stock and warrants, net of issuance costs of $1,333,449 (in shares)	13,624
Issuance of Series B convertible preferred stock and warrants, net of issuance costs of $1,333,449	$ 14	6,926,778		5,363,759		12,290,551
Allocation of Series B convertible preferred stock proceeds to beneficial conversion feature		(4,782,100)		4,782,100
Deemed Dividend on Series B convertible preferred stock		11,479,308		(11,479,308)
Conversion of Series B convertible preferred stock to common stock (in shares)	(10,107)		2,871,303
Conversion of Series B convertible preferred stock to common stock	$ (10)	(10,106,990)	$ 516,833	9,590,167
Amortization of commitment shares				(59,556)		(59,556)
Compensation cost for stock options granted to executives and employees				726,252		726,252
Net loss					(9,326,825)	(9,326,825)
Balance (in shares) at Sep. 30, 2018	3,517		5,523,255
Balance at Sep. 30, 2018	$ 4	$ 3,516,996	$ 994,175	$ 80,811,088	$ (74,753,154)	$ 10,569,109

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parentheticals)	9 Months Ended
	Sep. 30, 2018 USD ($)
Payments of Class A units issuance costs	$ 1,333,449

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (9,326,825)	$ (6,129,553)
Adjustments to reconcile net loss to net cash used in operating activities
Compensation cost for stock options granted	726,252	560,369
Loss on disposal of assets		17,695
Depreciation and amortization	28,690	102,074
Change in fair value of common stock warrants		280,747
Change in stock-based compensation liability	2,180,659
Warrant financing expense		192,817
Changes in operating assets and liabilities:
Prepaid expenses	(39,387)	14,195
Research and development tax rebate receivable	(122,218)
Accounts payable	215,803	126,079
Payroll liabilities	(78,717)	(142,312)
Accrued expenses	(38,432)	33,578
Other current liabilities	50,543	7,212
Net cash used in operating activities	(6,517,985)	(4,911,268)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of furniture, fixtures and equipment	(54,448)
Net cash used in investing activities	(54,448)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of warrants		745,333
Net cash provided by financing activities	12,290,551	4,616,969
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	5,718,118	(294,299)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE	7,272,469	3,082,962
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	12,990,587	2,788,663
NONCASH INVESTING AND FINANCING ACTIVITIES
Reclassification of warrant liability upon exercise of common stock warrants		1,893,160
Amount receivable for warrant exercise		3,900
Allocation of Class A and Class B Unit proceeds to warrant liability		1,612,413
Amortization of commitment shares issued for shares distributed for capital contribution	59,556	59,558
Units Consisting of Series B Convertible Preferred Stock and Warrants [Member]
CASH FLOWS FROM FINANCING ACTIVITIES
Proceed for issuance of Units, net of issuance costs	12,290,551
Class A and Class B Units [Member]
CASH FLOWS FROM FINANCING ACTIVITIES
Proceed for issuance of Units, net of issuance costs		3,871,636
Other Assets 1 [Member]
Changes in operating assets and liabilities:
Other assets	$ (114,353)	$ 25,831

Note 1 - Nature of Operations	9 Months Ended
Note 1 - Nature of Operations	Sep. 30, 2018
Notes to Financial Statements
Nature of Operations [Text Block]	NOTE 1: NATURE OF OPERATIONS Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company’s fiscal year ends on December 31. The Company is focused on development of its pharmaceutical and drug delivery programs.

Note 2 - Going Concern	9 Months Ended
Note 2 - Going Concern	Sep. 30, 2018
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2: GOING CONCERN The Company’s consolidated financial statements are prepared using Generally Accepted Accounting Principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative operating cash flows since inception. For the nine months ended September 30, 2018, the Company recorded a net loss of approximately $9.3 million and used approximately $6.5 million of cash in operating activities. As of September 30, 2018, the Company had approximately $12.9 million in cash and cash equivalents and working capital of approximately $10.4 million. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that any additional capital that it is able to obtain, if any, will be sufficient to meet its needs, or that any such capital will be obtained on acceptable terms. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail its activities. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern. Management’s plan to continue as a going concern includes obtaining additional capital resources. Management’s plans to obtain such resources for the Company include obtaining capital from the sale of its equity securities, entering into strategic partnership arrangements, potential exercise of outstanding warrants, and short-term borrowings from banks, stockholders or other related parties, if needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans. As of the date of filing this report, we expect that our existing resources will be sufficient to fund our planned operations for the next 9 to 15 months; however, additional capital resources will be needed to fund operations longer-term. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraphs and eventually to secure other sources of financing and attain profitable operations.

Note 3 - Summary of Accounting Policies	9 Months Ended
Note 3 - Summary of Accounting Policies	Sep. 30, 2018
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	NOTE 3: SUMMARY OF ACCOUNTING POLICIES Basis of Presentation: The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10 -Q and Rule 10 - 01 of Regulation S- X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10 -K of the Company for the year ended December 31, 2017. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. On April 20, 2018, the Company completed a 1 -for- 12 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 12 shares of issued and outstanding common stock were combined into one issued and outstanding share of common stock, and the par value per share was changed to $0.18 per share. The number of authorized shares of common stock was not reduced as a result of the Reverse Stock Split. The Company’s common stock began trading on a reverse stock split-adjusted basis on April 20, 2018. All share and per share data included in this report has been retroactively restated to reflect the Reverse Stock Split. Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Recently Issued Accounting Pronouncements: In February 2016, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016 - 02, Lease Accounting Topic 842. This ASU requires a lessee to recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. The new standard applies a right-of-use (ROU) model that requires a lessee to record, for all leases with a lease term of more than 12 months, an asset representing its right to use the underlying asset for the lease term and a liability to make lease payments. The lease term is the non-cancellable period of the lease, and includes both periods covered by an option to extend the lease, if the lessee is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the lessee is reasonably certain not to exercise that termination option. For leases with a lease term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. A lessee making this accounting policy election would recognize lease expense over the term of the lease, generally in a straight-line pattern. The lessor accounting remains largely consistent with existing GAAP. The new standard takes effect in 2019 for public entities. The Company has not currently adopted the provisions of ASU No. 2016 - 02 and believes that the impact of adopting ASU 2016 - 02 will not be material to its consolidated financial statements, though will require the recognition of an operating lease liability and right-of-use asset upon adoption, based on the lease composition disclosed in Footnote 11. In November 2016, the FASB issued ASU No. 2016 - 18, Statement of Cash Flows , amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The Company adopted the provisions of ASU No. 2016 - 18 as of January 1, 2018 and has included restricted cash with cash and cash equivalents on the accompanying statement of cash flows, including reclassifying 2017 balances. For the three and nine months ended September 30, 2018 and September 30, 2017, we included $55,000 of restricted cash in cash and cash equivalents on the statement of cash flows. The restricted cash represents a required deposit for the Company credit card and is restricted until the Company no longer has the credit card or the limit changes on the credit card. In July 2017, the FASB issued ASU 2017 - 11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception . Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2017 - 11 as of January 1, 2018. As the Company does not have any financial instruments with down round features, this ASU did not have a material impact on the financial statements upon adoption. In June 2018, the FASB issued ASU 2018 - 07, Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. This ASU simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide financing to the issuer or was granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers . This update is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2018 - 17 as of April 1, 2018 and it did not have a material impact on the financial statements upon adoption.

Note 4 - Prepaid Expenses

9 Months Ended

Sep. 30, 2018

Notes to Financial Statements

Prepaid Expenses [Text Block]

NOTE

PREPAID EXPENSES

Prepaid expenses consisted of the following:

	September 30,		December 31,
	2018		2017
Prepaid insurance	$	46,618	$	125,056
Retainer and security deposits		16,718		14,218
Professional services		93,557		97,788
Prepaid research and development		104,299
Financial exchange fees		13,750
Other		15,389		13,882
	$	290,331	$	250,944

Note 5 - Research and Development Tax Rebate Receivable	9 Months Ended
Note 5 - Research and Development Tax Rebate Receivable	Sep. 30, 2018
Notes to Financial Statements
Research and Development Tax Rebate Receivable [Text Block]	NOTE 5: RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE On May 23, 2017 Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform research and development activities (“R&D”) including our Phase 1 and Phase 2 Endoxifen clinical trials. Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country. For the nine months ended September 30, 2018, the Company incurred qualified R&D expenses of approximately $764,000 and recorded a rebate receivable of approximately $333,000 and a corresponding credit to R&D expenses for the nine months ended September 30, 2018. At September 30, 2018, we had a total R&D rebate receivable of approximately $481,000 that includes approximately $148,000 receivable remaining from the year ended December 31, 2017.

Note 6 - Payroll Liabilities

9 Months Ended

Sep. 30, 2018

Notes to Financial Statements

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]

NOTE

PAYROLL LIABILITIES

Payroll liabilities consisted of the following:

	September 30, 2018		December 31, 2017
Accrued bonus payable	$	480,917	$	566,000
Accrued vacation		156,775		147,861
Accrued payroll liabilities		68,458		71,006
Total payroll liabilities	$	706,150	$	784,867

Note 7 - Stockholders' Equity

9 Months Ended

Sep. 30, 2018

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

NOTE

STOCKHOLDERS’ EQUITY

The Company is authorized to issue a total of

185,000,000

shares of stock consisting of

175,000,000

shares of common stock, par value

$0.18

per share, and

10,000,000

shares of preferred stock, par value

$0.001

per share. The Company has designated

750,000

shares of Series A junior participating preferred stock, par value

$0.001

per share,

4,000

shares of Series A convertible preferred stock, par value

$0.001

per share, and

25,000

shares of Series B convertible preferred stock, par value

$0.001

per share, through the filings of certificates of designation with the Delaware Secretary of State.

shares of Series A junior participating preferred stock and

shares of Series A convertible preferred stock are issued and outstanding as of

September 30, 2018.

May 19, 2014,

the Company adopted a stockholder rights agreement which provides that all stockholders of record on

May 26, 2014

received a non-taxable distribution of

one

preferred stock purchase right for each share of the Company’s common stock held by such stockholder. Each right is attached to and trades with the associated share of common stock. The rights will become exercisable only if

one

of the following occurs: (

) a person becomes an “Acquiring Person” by acquiring beneficial ownership of

15%

or more of the Company’s common stock (or, in the case of a person who beneficially owned

15%

or more of the Company’s common stock on the date the stockholder rights agreement was executed, by acquiring beneficial ownership of additional shares representing

2.0%

of the Company’s common stock then outstanding (excluding compensatory arrangements)), or (

) a person commences a tender offer that, if consummated, would result in such person becoming an Acquiring Person. If a person becomes an Acquiring Person, each right will entitle the holder, other than the Acquiring Person and certain related parties, to purchase a number of shares of the Company’s common stock with a market value that equals twice the exercise price of the right. The initial exercise price of each right is

$15.00,

so each holder (other than the Acquiring Person and certain related parties) exercising a right would be entitled to receive

$30.00

worth of the Company’s common stock. If the Company is acquired in a merger or similar business combination transaction at any time after a person has become an Acquiring Person, each holder of a right (other than the Acquiring Person and certain related parties) will be entitled to purchase a similar amount of stock of the acquiring entity.

2018

Subscription Rights Offering of Units Consisting of Series B Convertible Preferred Stock and Warrants

May 9, 2018,

the Company’s Registration Statement on Form S-

with the Securities and Exchange Commission was declared effective to offer subscription rights to purchase up to

25,000

units at

$1,000

per unit with each unit consisting of

one

share of Series B convertible preferred stock and warrants to purchase

284

shares of common stock.

May 29, 2018,

the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B convertible preferred stock with the Delaware Secretary of State creating a new series of its authorized preferred stock, par value

$0.001

per share, designated as the Series B convertible preferred stock. The number of shares initially constituting the Series B preferred stock was set at

25,000

shares.

May 30, 2018,

the Company completed its previously announced rights offering pursuant to which the Company sold an aggregate of

13,624

units consisting of an aggregate of

13,624

shares of Series B convertible preferred stock and

3,869,216

warrants, with each warrant exercisable for

one

share of common stock at an exercise price of

$4.048

per share (the

“2018

Warrants”), resulting in net proceeds to the Company of approximately

$12.3

million, after deducting expenses relating to the rights offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants.

Series B Convertible Preferred Stock

The terms and provisions of our Series B convertible preferred stock are:

Conversion.

Each share of Series B convertible preferred stock is convertible at our option at any time on or after the

first

anniversary of the closing of the rights offering or at the option of the holder at any time, into the number of shares of our common stock determined by dividing the

$1,000

stated value per share of the Series B convertible preferred stock by a conversion price of

$3.52

per share. In addition, the conversion price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations or reclassifications. Subject to limited exceptions, a holder of the Series B convertible preferred stock will

not

have the right to convert any portion of the Series B convertible preferred stock to the extent that, after giving effect to the conversion, the holder, together with its affiliates, would beneficially own in excess of

9.99%

of the number of shares of our common stock outstanding immediately after giving effect to its conversion.

Fundamental Transactions.

In the event we effect certain mergers, consolidations, sales of substantially all of our assets, tender or exchange offers, reclassifications or share exchanges in which our common stock is effectively converted into or exchanged for other securities, cash or property, we consummate a business combination in which another person acquires

50%

of the outstanding shares of our common stock, or any person or group becomes the beneficial owner of

50%

of the aggregate ordinary voting power represented by our issued and outstanding common stock, then, upon any subsequent conversion of the Series B convertible preferred stock, the holders of the Series B convertible preferred stock will have the right to receive any shares of the acquiring corporation or other consideration it would have been entitled to receive if it had been a holder of the number of shares of common stock then issuable upon conversion in full of the Series B convertible preferred stock.

Dividends.

Holders of Series B convertible preferred stock shall be entitled to receive dividends (on an as-if-converted-to-common-stock basis) in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of common stock.

Voting Rights.

Except as otherwise provided in the certificate of designation or as otherwise required by law, the Series B convertible preferred stock has

voting rights.

Liquidation Preference

Upon our liquidation, dissolution or winding-up, whether voluntary or involuntary, holders of Series B convertible preferred stock will be entitled to receive out of our assets, whether capital or surplus, the same amount that a holder of common stock would receive if the Series B convertible preferred stock were fully converted (disregarding for such purpose any conversion limitations under the certificate of designation) to common stock, which amounts shall be paid pari passu with all holders of common stock.

Redemption Rights.

We are

not

obligated to redeem or repurchase any shares of Series B convertible preferred stock. Shares of Series B convertible preferred stock are

not

otherwise entitled to any redemption rights, or mandatory sinking fund or analogous provisions.

2018

Warrants

The terms and conditions of the warrants included in the

2018

rights offering are as follows:

Exercisability

. Each warrant is exercisable at any time and will expire

four

years from the date of issuance. The warrants are exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and payment in full for the number of shares of our common stock purchased upon such exercise, except in the case of a cashless exercise as discussed below.

The number of shares of common stock issuable upon exercise of the warrants is subject to adjustment in certain circumstances, including a stock split of, stock dividend on, or a subdivision, combination or recapitalization of the common stock. Upon the merger, consolidation, sale of substantially all of our assets, or other similar transaction, the holders of warrants shall, at the option of the company, be required to exercise the warrants immediately prior to the closing of the transaction, or such warrants shall automatically expire. Upon such exercise, the holders of warrants shall participate on the same basis as the holders of common stock in connection with the transaction.

Cashless Exercise

. If at any time there is

effective registration statement registering, or the prospectus contained therein is

not

available for issuance of, the shares issuable upon exercise of the warrant, the holder

may

exercise the warrant on a cashless basis. When exercised on a cashless basis, a portion of the warrant is cancelled in payment of the purchase price payable in respect of the number of shares of our common stock purchasable upon such exercise.

Exercise Price

. Each warrant represents the right to purchase

one

share of common stock at an exercise price of

$4.048

per share. In addition, the exercise price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations, or reclassifications, and for certain dilutive issuances. Subject to limited exceptions, a holder of warrants will

not

have the right to exercise any portion of the warrant to the extent that, after giving effect to the exercise, the holder, together with its affiliates, and any other person acting as a group together with the holder or any of its affiliates, would beneficially own in excess of

4.99%

of the number of shares of our common stock outstanding immediately after giving effect to its exercise. The holder, upon notice to the Company,

may

increase or decrease the beneficial ownership limitation provisions of the warrant, provided that in

event shall the limitation exceed

9.99%

of the number of shares of our common stock outstanding immediately after giving effect to the exercise of the warrant.

Transferability

. Subject to applicable laws and restrictions, a holder

may

transfer a warrant upon surrender of the warrant to us with a completed and signed assignment in the form attached to the warrant. The transferring holder will be responsible for any tax that liability that

may

arise as a result of the transfer.

Exchange Listing

. We do

not

intend to apply to list the warrants on any securities exchange or recognized trading system.

Rights as Stockholder

. Except as set forth in the warrant, the holder of a warrant, solely in such holder’s capacity as a holder of a warrant, will

not

be entitled to vote, to receive dividends, or to any of the other rights of our stockholders.

Redemption Rights

. We

may

redeem the warrants for

$0.18

per warrant if the volume-weighted-average-price of our common stock equals or exceeds

$10.56

per share for

ten

consecutive trading days, provided that we

may

not

do so prior to the

first

anniversary of closing of the rights offering.

Accounting Treatment

The Company allocated the proceeds from the sale of the Series B convertible preferred stock and the warrants to purchase common stock to the separate securities issued. The Company allocated the amount representing the fair value of the warrants at the date of issuance to common stock based on the relative warrant fair value in the amount of

$5,363,759,

which is net of issuance costs allocated to the warrants. Due to the allocation of a portion of the proceeds to the warrants, the convertible preferred stock contained a beneficial conversion feature upon issuance, which was recorded in the amount of

$4,782,100

based on the relative fair value of the beneficial conversion feature. The discount on the convertible preferred stock was

$11,479,308,

which consists of the beneficial conversion feature of

$4,782,100,

the allocation of a portion of the proceeds to the warrants in the amount of

$5,363,759,

and the total issuance costs related to the financing of

$1,333,449.

The discount on the convertible preferred stock of

$11,479,308

was recorded as a deemed dividend upon issuance of the convertible preferred stock. The deemed dividend is reflected as an addition to net loss in the condensed consolidated statements of operations to arrive at net loss applicable to common shareholders. The Company has made an accounting policy election to record the deemed dividend related to discounts on convertible instruments at the time of issuance of the convertible instruments.

Outstanding Warrants

As of

September 30, 2018,

warrants to purchase

4,318,475

shares of common stock were outstanding including:

	Outstanding Warrants to Purchase Shares		Exercise Price			Expiration Date

2014 public offering		6,483		$540.00		January 29, 2019
Placement agent fees for Company’s offerings		1,106	381.60	–	540.00	November 4, 2018
2017 Warrant B private placement		441,670		3.78		December 22, 2018
2018 Warrants		3,869,216		4.05		May 30, 2022
		4,318,475

Conversion of Series B Convertible Preferred Stock

During the

three

and

nine

months ended

September 30, 2018,

certain holders of the Series B convertible preferred stock exercised their conversion option and converted an aggregate of

2,285

and

10,107

shares, respectively, into

649,156

and

2,871,303

shares, respectively, of the Company's common stock based on the conversion ratio of approximately

284

shares of common stock for each share of Series B convertible preferred stock.

Note 8 - Net Loss Per Share

9 Months Ended

Sep. 30, 2018

Notes to Financial Statements

Earnings Per Share [Text Block]

NOTE

NET LOSS PER SHARE

The Company accounts for and discloses net income (loss) per common share in accordance with Accounting Standards Codification ("ASC") Topic

260,

Earnings Per Share

. Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back any convertible preferred dividends. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of potential future exercises of outstanding stock options and common stock warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented they have been excluded from the calculation.

The following table summarizes the Company’s calculation of net loss per common share:

	Three Months Ended September 30,						Nine months Ended September 30,
	2018			2017			2018			2017
Net Loss Per Share
Numerator
Net loss	$	(3,309,866	)	$	(2,184,510	)	$	(9,326,825	)	$	(6,129,553	)
Deemed dividend attributable to preferred stock								(11,479,308	)		(2,568,132	)
Net loss attributable to common shareholders	$	(3,309,866	)	$	(2,184,510	)	$	(20,806,133	)	$	(8,697,685	)
Denominator
Weighted average common shares outstanding		5,183,492			1,034,262			3,645,682			657,184
Basic and diluted net loss per share	$	(0.64	)	$	(2.11	)	$	(5.71	)	$	(13.23	)

The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share for the

three

and

nine

months ended

September 30, 2018

and

2017

because including them would be anti-dilutive:

	Three Months Ended September 30,				Nine months Ended September 30,
	2018		2017		2018		2017
Options to purchase common stock		783,794		176,502		388,377		100,505
Series A convertible preferred stock				42,480				74,651
Series B convertible preferred stock		1,338,916				751,332
Warrants to purchase common stock		4,716,935		138,365		2,644,946		227,229
Total		6,839,645		357,347		3,784,655		402,385

For the

three

and

nine

months ended

September 30, 2018

and

2017,

the average price of our common stock was less than the exercise price of the vested stock options and exercisable warrants.

Note 9 - Income Taxes	9 Months Ended
Note 9 - Income Taxes	Sep. 30, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 9: INCOME TAXES Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No income tax liabilities existed as of September 30, 2018 and December 31, 2017 due to the Company’s continuing operating losses.

Note 10 - Concentration of Credit Risk	9 Months Ended
Note 10 - Concentration of Credit Risk	Sep. 30, 2018
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE 10: CONCENTRATION OF CREDIT RISK Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At September 30, 2018 and December 31, 2017, the Company had $12,685,587 and $6,967,469 in excess of the FDIC insured limit, respectively.

Note 11 - Commitments and Contingencies	9 Months Ended
Note 11 - Commitments and Contingencies	Sep. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 11: COMMITMENTS AND CONTINGENCIES Lease Commitments On November 1, 2018, the Company entered into an operating lease to pay $3,660 monthly rent for a term of 22 months. The total future minimum lease payments due under this lease are $80,500. Litigation and Contingencies On October 10, 2013, a putative securities class action complaint, captioned Cook v. Atossa Genetics, Inc., et al. , No. 2:13 -cv- 01836 -RSM, was filed in the United States District Court for the Western District of Washington against us, certain of our directors and officers and the underwriters of our November 2012 initial public offering. The complaint alleged that all defendants violated Sections 11 and 12 (a)( 2 ), and that we and certain of our directors and officers violated Section 15, of the Securities Act by making material false and misleading statements and omissions in the offering’s registration statement, and that we and certain of our directors and officers violated Sections 10 (b) and 20A of the Exchange Act and SEC Rule 10b - 5 promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device. The complaint sought, on behalf of persons who purchased our common stock between November 8, 2012 and October 4, 2013, inclusive, damages of an unspecific amount. On March 23, 2018, the parties filed a stipulation of settlement with the court to settle the matter for $3.5 million, completely funded by defendants’ insurers, and on July 20, 2018 the Court approved the settlement. This case is considered closed as of September 30, 2018. We are subject to other legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should not have a material effect, individually or in the aggregate, on our financial position, results of operations or cash flows.

Note 12 - Stock Based Compensation

9 Months Ended

Sep. 30, 2018

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

NOTE

12:

STOCK BASED COMPENSATION

Stock Option and Incentive Plan

September 28, 2010,

the Board of Directors approved the adoption of the

2010

Stock Option and Incentive Plan the (

“2010

Plan”) to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options

may

be granted under the

2010

Plan until

September 2020.

other awards

may

be granted under the

2010

Plan after the date that is

years from the date of stock-holder approval. An aggregate of

5,556

shares were initially reserved for issuance in connection with awards granted under the

2010

Plan and on

May 18, 2016,

an additional

11,111

shares were reserved for issuance under the

2010

Plan. On

May 9, 2017,

the stockholders approved an additional

125,000

shares for issuance under the

2010

Plan. On

April 12, 2018,

the stockholders approved an additional

500,000

shares for issuance under the

2010

Plan.

The following table presents the automatic additions to the

2010

Plan since inception pursuant to the “evergreen” terms of the

2010

Plan:

January 1,	Number of shares
2012		2,502
2013		2,871
2014		4,128
2015		5,463
2016		18,368
2017		12,623
2018		106,076
Total additional shares		152,031

The Company did

not

grant options to purchase shares of common stock during the

three

months ended

September 30, 2018

2017.

options were exercised during the

three

nine

months ended

September 30, 2018.

There are

3,197

shares available for grant under the

2010

Plan as of

September 30, 2018.

Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of

$332,063

and

$224,254

for the

three

months ended

September 30, 2018

and

2017,

respectively and

$726,252

and

$560,369

for the

nine

months ended

September 30, 2018

and

2017,

respectively (excluding the liability options discussed below).

Options issued and outstanding as of

September 30, 2018

under the

2010

Plan and their activities during the

nine

months then ended are as follows:

	Number of Underlying Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Contractual Life Remaining in Years		Aggregate Intrinsic Value
Outstanding as of January 1, 2018		172,510		$	49.27			$
Granted		611,668			2.39
Forfeited		(417	)		5.64
Expired
Outstanding as of September 30, 2018		783,761			12.70		9.42	$
Exercisable as of September 30, 2018		199,949			40.62		8.95	$
Vested and expected to vest		783,761			12.70		9.42	$

September 30, 2018,

there were

583,812

unvested options outstanding and the related unrecognized total compensation cost associated with these options was approximately

$1,479,610.

This expense is expected to be recognized over a weighted-average period of

1.56

years.

Option Grants Classified as Liabilities (“Liability Grants”)

June 27, 2018,

the Company granted

2,300,000

options to the Chief Executive Officer and

700,000

to the Chief Financial Officer. Each option is exercisable for an equivalent number of shares of Company common stock. The options were granted pursuant to an option award agreement and were granted outside the Company’s

2010

Plan; however, they are subject to the terms and conditions of the

2010

Plan.

The Liability Grants are exercisable for shares of common stock at an exercise price of

$2.38

per share, which was the fair market value on the date of grant. The options have an exercise period of

ten

years from their date of issuance. If at the time the options are exercised the Company cannot deliver shares of common stock to the optionee including, for example, if there are insufficient shares available under the Plan at the time of exercise, then in lieu of the optionee paying the exercise price and the Company issuing shares of stock, the option

may

only be exercised on a cash “net basis” so that the Company will pay cash in an amount equal to the excess of the fair market value of the common stock over the option exercise price. There currently are

not

sufficient shares available under the Plan and the Company would be obligated to settle these options in cash if they were exercised. Because these options contain provisions that could require the Company to settle the options in cash in an event outside the Company’s control, they are accounted for as liabilities.

The Liability Grants are subject to vesting requirements. Twenty-

five

percent of the options have vested as of the grant date,

50%

of the options will vest quarterly over

two

years, and the remaining

25%

vest upon achievement of certain milestones related to clinical trial progress. As of

September 30 2018,

80%

of the options that vest upon achievement of clinical trial milestones are vested.

Compensation costs associated with the Liability Grants are initially recognized, based on the grant-date fair values of these options, over the requisite or vesting period for time-based options or when it is probable the performance criteria will be achieved for options that vest based on performance. Compensation cost is remeasured each period based on the market value of our underlying stock until award vesting or settlement.

For the

three

and

nine

months ended

September 30, 2018,

the Company recognized compensation expense related to these options of

$623,496

and

$2,180,659,

respectively.

The fair value of liability options granted for the

nine

months ended

September 30, 2018

was calculated using the Black-Scholes option-pricing model applying the following assumptions:

	Nine months ended September 30,
	2018

Risk free interest rate	2.94	%
Expected term (in years)	4.75
Stock price	$1.75
Dividend yield		%
Expected volatility	122.0	%

Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements

9 Months Ended

Sep. 30, 2018

Notes to Financial Statements

Reclassifications [Text Block]

NOTE

13:

RESTATEMENT TO PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The Company has corrected an inadvertent error in the calculation of the deemed dividend on Series B convertible preferred stock in the financial statements for the

three

and

six

months ended

June 30, 2018

that were included in the Company’s Form

-Q filed on

August 13, 2018 (

the “Original Form

-Q”). Accounting principles generally accepted in the United States of America require that we allocate the proceeds from the

May 2018

financing to the warrants and preferred stock issued in the financing and that we estimate and record any discount on the securities as a deemed dividend. In the financial statements included in the Original Form

-Q, we did

not

properly allocate the proceeds to the warrants, and we did

not

properly record the deemed dividend related to the warrant discount as additional paid in capital to common stock. The Company incorrectly stated the deemed dividend for the

three

and

six

months ended

June 30, 2018

$4,782,100

rather than

$11,479,308

The corrections result from application of technical accounting rules and do

not

impact cash or operations.

In accordance with applicable generally accepted accounting principles, the Company has calculated and recognized adjustments accordingly. The following table shows the effect of the restatement on certain line items within the Company’s Condensed Consolidated Statement of Operations for the

three

months and

six

months ended

June 30, 2018:

	For the Three Months Ended June 30, 2018						For the Six Months Ended June 30, 2018
	Previously Reported			Restated			Previously Reported			Restated
Deemed dividend attributable to preferred stock	$	(4,782,100	)	$	(11,479,308	)	$	(4,782,100	)	$	(11,479,308	)
Net loss applicable to common stockholders	$	(8,924,677	)	$	(15,621,885	)	$	(10,799,059	)	$	(17,496,267	)
Loss per common share -basic and diluted	$	(2.90	)	$	(5.08	)	$	(3.77	)	$	(6.11	)

The following table shows the effect of the restatement on certain line items within the Company’s Condensed Consolidated Statement of Stockholders’ Equity for the

six

months ended

June 30, 2018:

	Preferred Stock Additional Paid-in Capital						Common Stock Additional Paid-in Capital
	Previously Reported			Restated			Previously Reported			Restated
Issuance of Series B convertible preferred stock, net of issuance costs	$	12,290,537		$	6,926,778		$	0		$	5,363,759
Deemed Dividend on Series B convertible preferred stock	$	4,782,100		$	11,479,308		$	(4,782,100	)	$	(11,479,308	)
Conversion of Series B convertible preferred stock to common stock	$	(7,056,421	)	$	(7,821,992	)	$	6,656,442		$	7,422,013

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation: The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10 -Q and Rule 10 - 01 of Regulation S- X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10 -K of the Company for the year ended December 31, 2017. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. On April 20, 2018, the Company completed a 1 -for- 12 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 12 shares of issued and outstanding common stock were combined into one issued and outstanding share of common stock, and the par value per share was changed to $0.18 per share. The number of authorized shares of common stock was not reduced as a result of the Reverse Stock Split. The Company’s common stock began trading on a reverse stock split-adjusted basis on April 20, 2018. All share and per share data included in this report has been retroactively restated to reflect the Reverse Stock Split.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements: In February 2016, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016 - 02, Lease Accounting Topic 842. This ASU requires a lessee to recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. The new standard applies a right-of-use (ROU) model that requires a lessee to record, for all leases with a lease term of more than 12 months, an asset representing its right to use the underlying asset for the lease term and a liability to make lease payments. The lease term is the non-cancellable period of the lease, and includes both periods covered by an option to extend the lease, if the lessee is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the lessee is reasonably certain not to exercise that termination option. For leases with a lease term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. A lessee making this accounting policy election would recognize lease expense over the term of the lease, generally in a straight-line pattern. The lessor accounting remains largely consistent with existing GAAP. The new standard takes effect in 2019 for public entities. The Company has not currently adopted the provisions of ASU No. 2016 - 02 and believes that the impact of adopting ASU 2016 - 02 will not be material to its consolidated financial statements, though will require the recognition of an operating lease liability and right-of-use asset upon adoption, based on the lease composition disclosed in Footnote 11. In November 2016, the FASB issued ASU No. 2016 - 18, Statement of Cash Flows , amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The Company adopted the provisions of ASU No. 2016 - 18 as of January 1, 2018 and has included restricted cash with cash and cash equivalents on the accompanying statement of cash flows, including reclassifying 2017 balances. For the three and nine months ended September 30, 2018 and September 30, 2017, we included $55,000 of restricted cash in cash and cash equivalents on the statement of cash flows. The restricted cash represents a required deposit for the Company credit card and is restricted until the Company no longer has the credit card or the limit changes on the credit card. In July 2017, the FASB issued ASU 2017 - 11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception . Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2017 - 11 as of January 1, 2018. As the Company does not have any financial instruments with down round features, this ASU did not have a material impact on the financial statements upon adoption. In June 2018, the FASB issued ASU 2018 - 07, Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. This ASU simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide financing to the issuer or was granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers . This update is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2018 - 17 as of April 1, 2018 and it did not have a material impact on the financial statements upon adoption.

Note 4 - Prepaid Expenses (Tables)

9 Months Ended

Sep. 30, 2018

Notes Tables

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]

	September 30,		December 31,
	2018		2017
Prepaid insurance	$	46,618	$	125,056
Retainer and security deposits		16,718		14,218
Professional services		93,557		97,788
Prepaid research and development		104,299
Financial exchange fees		13,750
Other		15,389		13,882
	$	290,331	$	250,944

Note 6 - Payroll Liabilities (Tables)

9 Months Ended

Sep. 30, 2018

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

	September 30, 2018		December 31, 2017
Accrued bonus payable	$	480,917	$	566,000
Accrued vacation		156,775		147,861
Accrued payroll liabilities		68,458		71,006
Total payroll liabilities	$	706,150	$	784,867

Note 7 - Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2018

Notes Tables

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

	Outstanding Warrants to Purchase Shares		Exercise Price			Expiration Date

2014 public offering		6,483		$540.00		January 29, 2019
Placement agent fees for Company’s offerings		1,106	381.60	–	540.00	November 4, 2018
2017 Warrant B private placement		441,670		3.78		December 22, 2018
2018 Warrants		3,869,216		4.05		May 30, 2022
		4,318,475

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Note 8 - Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2018

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended September 30,						Nine months Ended September 30,
	2018			2017			2018			2017
Net Loss Per Share
Numerator
Net loss	$	(3,309,866	)	$	(2,184,510	)	$	(9,326,825	)	$	(6,129,553	)
Deemed dividend attributable to preferred stock								(11,479,308	)		(2,568,132	)
Net loss attributable to common shareholders	$	(3,309,866	)	$	(2,184,510	)	$	(20,806,133	)	$	(8,697,685	)
Denominator
Weighted average common shares outstanding		5,183,492			1,034,262			3,645,682			657,184
Basic and diluted net loss per share	$	(0.64	)	$	(2.11	)	$	(5.71	)	$	(13.23	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three Months Ended September 30,				Nine months Ended September 30,
	2018		2017		2018		2017
Options to purchase common stock		783,794		176,502		388,377		100,505
Series A convertible preferred stock				42,480				74,651
Series B convertible preferred stock		1,338,916				751,332
Warrants to purchase common stock		4,716,935		138,365		2,644,946		227,229
Total		6,839,645		357,347		3,784,655		402,385

Note 12 - Stock Based Compensation (Tables)

9 Months Ended

Sep. 30, 2018

Notes Tables

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

January 1,	Number of shares
2012		2,502
2013		2,871
2014		4,128
2015		5,463
2016		18,368
2017		12,623
2018		106,076
Total additional shares		152,031

Share-based Compensation, Stock Options, Activity [Table Text Block]

	Number of Underlying Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Contractual Life Remaining in Years		Aggregate Intrinsic Value
Outstanding as of January 1, 2018		172,510		$	49.27			$
Granted		611,668			2.39
Forfeited		(417	)		5.64
Expired
Outstanding as of September 30, 2018		783,761			12.70		9.42	$
Exercisable as of September 30, 2018		199,949			40.62		8.95	$
Vested and expected to vest		783,761			12.70		9.42	$

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Nine months ended September 30,
	2018

Risk free interest rate	2.94	%
Expected term (in years)	4.75
Stock price	$1.75
Dividend yield		%
Expected volatility	122.0	%

Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Tables)

9 Months Ended

Sep. 30, 2018

Notes Tables

Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]

	For the Three Months Ended June 30, 2018						For the Six Months Ended June 30, 2018
	Previously Reported			Restated			Previously Reported			Restated
Deemed dividend attributable to preferred stock	$	(4,782,100	)	$	(11,479,308	)	$	(4,782,100	)	$	(11,479,308	)
Net loss applicable to common stockholders	$	(8,924,677	)	$	(15,621,885	)	$	(10,799,059	)	$	(17,496,267	)
Loss per common share -basic and diluted	$	(2.90	)	$	(5.08	)	$	(3.77	)	$	(6.11	)

	Preferred Stock Additional Paid-in Capital						Common Stock Additional Paid-in Capital
	Previously Reported			Restated			Previously Reported			Restated
Issuance of Series B convertible preferred stock, net of issuance costs	$	12,290,537		$	6,926,778		$	0		$	5,363,759
Deemed Dividend on Series B convertible preferred stock	$	4,782,100		$	11,479,308		$	(4,782,100	)	$	(11,479,308	)
Conversion of Series B convertible preferred stock to common stock	$	(7,056,421	)	$	(7,821,992	)	$	6,656,442		$	7,422,013

Note 2 - Going Concern (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
Note 2 - Going Concern (Details Textual) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Net Income (Loss) Attributable to Parent, Total	$ (3,309,866)	$ (2,184,510)	$ (9,326,825)	$ (6,129,553)
Net Cash Provided by (Used in) Operating Activities, Total			(6,517,985)	$ (4,911,268)
Cash and Cash Equivalents, at Carrying Value, Ending Balance	12,935,587		12,935,587		$ 7,217,469
Working Capital	$ 10,400,000		$ 10,400,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Note 3 - Summary of Accounting Policies (Details Textual)	Apr. 20, 2018	Sep. 30, 2018 USD ($) $ / shares	Dec. 31, 2017 $ / shares	Sep. 30, 2017 USD ($)
Common Stock, Par or Stated Value Per Share \| $ / shares		$ 0.18	$ 0.18
Restricted Cash and Cash Equivalents, Total \| $		$ 55,000		$ 55,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	12

Note 4 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Prepaid insurance	$ 46,618	$ 125,056
Retainer and security deposits	16,718	14,218
Professional services	93,557	97,788
Prepaid research and development	104,299
Financial exchange fees	13,750
Other	15,389	13,882
	$ 290,331	$ 250,944

Note 5 - Research and Development Tax Rebate Receivable (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	May 23, 2017
Research and Development Expense, Total	$ 1,421,851	$ 742,450	$ 3,360,563	$ 2,110,846
Increase (Decrease) in Research and Development Tax Rebate Receivable			122,218
Research and Development Tax Rebate Receivable	480,495		480,495		$ 358,277
Atossa Genetics AUS Pty Ltd [Member]
Research and Development Cash Rebate per Dollar						$ 0.435
Research and Development Expense, Total			764,000
Increase (Decrease) in Research and Development Tax Rebate Receivable			333,000
Research and Development Tax Rebate Receivable	$ 481,000		$ 481,000		$ 148,000

Note 6 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accrued bonus payable	$ 480,917	$ 566,000
Accrued vacation	156,775	147,861
Accrued payroll liabilities	68,458	71,006
Total payroll liabilities	$ 706,150	$ 784,867

Note 7 - Stockholders' Equity (Details Textual)		3 Months Ended			6 Months Ended	9 Months Ended
Note 7 - Stockholders' Equity (Details Textual)	May 30, 2018 USD ($) $ / shares shares	Sep. 30, 2018 USD ($) $ / shares shares	Jun. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2018 USD ($)	Sep. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2017 USD ($)	May 29, 2018 $ / shares	May 09, 2018 $ / item shares	Dec. 31, 2017 $ / shares shares	May 19, 2014 $ / shares shares
Number of Shares Authorized to Issue		185,000,000				185,000,000
Common Stock, Shares Authorized		175,000,000				175,000,000				175,000,000
Common Stock, Par or Stated Value Per Share \| $ / shares		$ 0.18				$ 0.18				$ 0.18
Preferred Stock, Shares Authorized		10,000,000				10,000,000				10,000,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares		$ 0.001				$ 0.001				$ 0.001
Stockholder Rights Agreement, Number of Preferred Stock Right Distributed for Each Share of Common Stock											1
Stockholder Rights Agreement, Acquiring Person, Percentage of Ownership											15.00%
Stockholder Rights Agreement, Acquiring Person, Additional Percentage of Ownership											2.00%
Stockholder Rights Agreement, Initial Exercise Price of Each Right \| $ / shares											$ 15
Stockholder Rights Agreement, Share Price \| $ / shares											$ 30
Class of Warrant or Right, Outstanding		4,318,475				4,318,475
Consummate a Business Combination, Percentage of Acquired Outstanding Shares		50.00%				50.00%
Consummate a Business Combination, Percentage of Aggregate Ordinary Voting Power		50.00%				50.00%
Preferred Stock, Deemed Dividend \| $			$ 11,479,308		$ 11,479,308	$ 11,479,308	$ 2,568,132
Payments of Stock Issuance Costs \| $						$ 1,333,449
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		4,318,475				4,318,475
Conversion of Stock, Shares Converted		2,285				10,107
The 2018 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 4.048	$ 4.048				$ 4.048
Warrants and Rights Outstanding, Term		4 years				4 years
Warrants Exercisable, Ownership Percentage of Company’s Shares Allowed		4.99%				4.99%
Warrants and Rights Outstanding, Redemption Price \| $ / shares		$ 0.18				$ 0.18
Warrants and Rights Outstanding, Redeemable, Volume-weighted-average-price of Our Common Stock \| $ / shares		$ 10.56				$ 10.56
The 2018 Subscription Rights Offering [Member]
Number of Units Authorized to Purchase, Maximum									25,000
Purchase Price of Unit \| $ / item									1,000
Number of Series B Convertible Preferred Stock and Warrant in Each Unit									1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right									284
Number of Units Sold	13,624
Proceeds from Issuance of Stock units \| $	$ 12,300,000
Adjustments to Additional Paid in Capital, Beneficial Conversion Feature on Preferred Stock \| $						$ 4,782,100
Preferred Stock, Deemed Dividend \| $						11,479,308
Payments of Stock Issuance Costs \| $						1,333,449
The 2018 Subscription Rights Offering [Member] \| The 2018 Warrants [Member]
Class of Warrant or Right, Outstanding	3,869,216
Warrants Allocated to Common Stock , Net of Issuance Cost \| $		$ 5,363,759				$ 5,363,759
Series A Junior Participating Preferred Stock [Member]
Preferred Stock, Shares Authorized		750,000				750,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares		$ 0.001				$ 0.001
Preferred Stock, Shares Issued, Total		0				0
Preferred Stock, Shares Outstanding, Ending Balance		0				0
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized		4,000				4,000				4,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares		$ 0.001				$ 0.001				$ 0.001
Preferred Stock, Shares Issued, Total		0				0
Preferred Stock, Shares Outstanding, Ending Balance		0				0				0
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized		25,000				25,000				0
Preferred Stock, Par or Stated Value Per Share \| $ / shares		$ 0.001				$ 0.001		$ 0.001		$ 0.001
Preferred Stock, Shares Issued, Total		3,517				3,517				0
Stated Value per Share \| $ / shares		1,000				1,000
Preferred Stock, Convertible, Conversion Price \| $ / shares		$ 3.52				$ 3.52
Preferred Stock, Convertible, Ownership Percentage of Company’s Shares Allowed		9.99%				9.99%
Convertible Preferred Stock, Shares Issued upon Conversion		284				284
Preferred Stock, Shares Outstanding, Ending Balance		3,517				3,517				0
Series B Convertible Preferred Stock [Member] \| The 2018 Subscription Rights Offering [Member]
Stock Issued During Period, Shares, New Issues	13,624
Common Stock [Member]
Conversion of Stock, Shares Issued		649,156				2,871,303

Note 7 - Stockholders' Equity - Schedule of Warrants (Details)	9 Months Ended
	Sep. 30, 2018 $ / shares shares
Class of Warrant or Right, Outstanding (in shares) \| shares	4,318,475
The 2014 Public Offering [Member]
Class of Warrant or Right, Outstanding (in shares) \| shares	6,483
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 540
Expiration Dates of Class of Warrant or Right	January 29, 2019
Placement Agent Fee [Member]
Class of Warrant or Right, Outstanding (in shares) \| shares	1,106
Expiration Dates of Class of Warrant or Right	November 4, 2018
Placement Agent Fee [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 381.60
Placement Agent Fee [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 540
The 2017 Warrant B Private Placement [Member]
Class of Warrant or Right, Outstanding (in shares) \| shares	441,670
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 3.78
Expiration Dates of Class of Warrant or Right	December 22, 2018
The 2018 Warrants [Member]
Class of Warrant or Right, Outstanding (in shares) \| shares	3,869,216
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 4.05
Expiration Dates of Class of Warrant or Right	May 30, 2022

Note 8 - Net Loss Per Share - Schedule of Earnings Per Share (Details) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Net loss	$ (3,309,866)		$ (2,184,510)		$ (9,326,825)	$ (6,129,553)
Deemed dividend attributable to preferred stock		$ (11,479,308)		$ (11,479,308)	(11,479,308)	(2,568,132)
Net loss applicable to common stockholders	$ (3,309,866)	$ (15,621,885)	$ (2,184,510)	$ (17,496,267)	$ (20,806,133)	$ (8,697,685)
Weighted average shares outstanding - basic and diluted (in shares)	5,183,492		1,034,262		3,645,682	657,184
Loss per common share -basic and diluted (in dollars per share)	$ (0.64)	$ (5.08)	$ (2.11)	$ (6.11)	$ (5.71)	$ (13.23)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Note 8 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Number of potential common shares excluded (in shares)	6,839,645	357,347	3,784,655	402,385
Employee Stock Option [Member]
Number of potential common shares excluded (in shares)	783,794	176,502	388,377	100,505
Series A Convertible Preferred Stock [Member]
Number of potential common shares excluded (in shares)		42,480		74,651
Series B Convertible Preferred Stock [Member]
Number of potential common shares excluded (in shares)	1,338,916		751,332
Warrant [Member]
Number of potential common shares excluded (in shares)	4,716,935	138,365	2,644,946	227,229

Note 9 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Accrued Income Taxes, Total	$ 0	$ 0

Note 10 - Concentration of Credit Risk (Details Textual) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Cash, Uninsured Amount	$ 12,685,587	$ 6,967,469

Note 11 - Commitments and Contingencies (Details Textual) - USD ($)	Nov. 01, 2018	Mar. 23, 2018
Loss Contingency, Damages Paid, Value		$ 3,500,000
Subsequent Event [Member]
Operating Lease, Lessee, Monthly Rent Expense	$ 3,660
Lessee, Operating Lease, Term of Contract	1 year 300 days
Operating Leases, Future Minimum Payments Due, Total	$ 80,500

Note 12 - Stock Based Compensation (Details Textual) - USD ($)						3 Months Ended		9 Months Ended
	Jun. 27, 2018	Apr. 12, 2018	May 09, 2017	May 18, 2016	Sep. 28, 2010	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Liability Options [Member]
Allocated Share-based Compensation Expense, Total						$ 623,496		$ 2,180,659
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 2.38
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards Vested						80.00%		80.00%
Liability Options [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Liability Options [Member] \| Share-based Compensation Award, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Liability Options [Member] \| Share-based Compensation Award, Tranche Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Liability Options [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Liability Options [Member] \| Chairman of the Board, President and Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,300,000
Liability Options [Member] \| Chief Financial Officer, General Counsel and Secretary [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	700,000
The 2010 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Period for Granting Shares					10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								611,668
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price								$ 2.39
The 2010 Stock Option and Incentive Plan [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					5,556
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		500,000	125,000	11,111
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period						0		0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant						3,197		3,197
Allocated Share-based Compensation Expense, Total						$ 332,063	$ 224,254	$ 726,252	$ 560,369
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance						583,812		583,812
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options						$ 1,479,610		$ 1,479,610
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition								1 year 204 days

Note 12 - Stock Based Compensation - Additional Shares Authorized (Details) - shares	12 Months Ended							84 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2017
The 2010 Stock Option and Incentive Plan [Member]
Total additional shares (in shares)	106,076	12,623	18,368	5,463	4,128	2,871	2,502	152,031

Note 12 - Stock Based Compensation - Stock Option Activity (Details) - The 2010 Stock Option and Incentive Plan [Member] - USD ($)	9 Months Ended
	Sep. 30, 2018
Outstanding, shares (in shares)	172,510
Outstanding, Weighted average exercise price per share (in dollars per share)	$ 49.27
Granted, shares (in shares)	611,668
Granted, Weighted average exercise price per share (in dollars per share)	$ 2.39
Forfeited, shares (in shares)	(417)
Forfeited, Weighted average exercise price per share (in dollars per share)	$ 5.64
Expired, shares (in shares)
Expired, Weighted average exercise price per share (in dollars per share)
Outstanding, shares (in shares)	783,761
Outstanding, Weighted average exercise price per share (in dollars per share)	$ 12.70
Outstanding, weighted average contractual life remaining in years (Year)	9 years 153 days
Outstanding, Aggregate intrinsic value
Exercisable, shares (in shares)	199,949
Exercisable, Weighted average exercise price per share (in dollars per share)	$ 40.62
Exercisable, weighted average contractual life remaining in years (Year)	8 years 346 days
Exercisable, Aggregate intrinsic value
Vested and expected to vest, shares (in shares)	783,761
Vested and expected to vest, Weighted average exercise price per share (in dollars per share)	$ 12.70
Vested and expected to vest, weighted average contractual life remaining in years (Year)	9 years 153 days
Vested and expected to vest, Aggregate intrinsic value

Note 12 - Stock Based Compensation - Valuation Assumptions (Details) - Liability Options [Member]	9 Months Ended
	Sep. 30, 2018 $ / shares
Risk free interest rate	2.94%
Expected term (in years) (Year)	4 years 273 days
Stock price (in dollars per share)	$ 1.75
Dividend yield
Expected volatility	122.00%

Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Details Textual) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Preferred Stock, Deemed Dividend		$ 11,479,308		$ 11,479,308	$ 11,479,308	$ 2,568,132
Series B Convertible Preferred Stock [Member]
Deemed Dividend on Series B Convertible Preferred Stock		11,479,308		11,479,308
Previously Reported [Member]
Preferred Stock, Deemed Dividend		4,782,100		4,782,100
Previously Reported [Member] \| Series B Convertible Preferred Stock [Member]
Preferred Stock, Deemed Dividend		$ 4,782,100		$ 4,782,100

Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements - Restatements (Details) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Deemed dividend attributable to preferred stock		$ (11,479,308)		$ (11,479,308)	$ (11,479,308)	$ (2,568,132)
Net loss applicable to common stockholders	$ (3,309,866)	$ (15,621,885)	$ (2,184,510)	$ (17,496,267)	$ (20,806,133)	$ (8,697,685)
Loss per common share -basic and diluted (in dollars per share)	$ (0.64)	$ (5.08)	$ (2.11)	$ (6.11)	$ (5.71)	$ (13.23)
Issuance of Series B convertible preferred stock, net of issuance costs					$ 12,290,551
Deemed Dividend on Series B convertible preferred stock
Conversion of Series B convertible preferred stock to common stock
Additional Paid in Capital, Convertible Preferred Stock [Member]
Issuance of Series B convertible preferred stock, net of issuance costs		$ 6,926,778			6,926,778
Deemed Dividend on Series B convertible preferred stock		11,479,308			11,479,308
Conversion of Series B convertible preferred stock to common stock		(7,821,992)			(10,106,990)
Additional Paid in Capital, Common Stock [Member]
Issuance of Series B convertible preferred stock, net of issuance costs				$ 5,363,759	5,363,759
Deemed Dividend on Series B convertible preferred stock				(11,479,308)	(11,479,308)
Conversion of Series B convertible preferred stock to common stock				7,422,013	$ 9,590,167
Previously Reported [Member]
Deemed dividend attributable to preferred stock		(4,782,100)		(4,782,100)
Net loss applicable to common stockholders		$ (8,924,677)		$ (10,799,059)
Loss per common share -basic and diluted (in dollars per share)		$ (2.90)		$ (3.77)
Previously Reported [Member] \| Additional Paid in Capital, Convertible Preferred Stock [Member]
Issuance of Series B convertible preferred stock, net of issuance costs		$ 12,290,537
Deemed Dividend on Series B convertible preferred stock		4,782,100
Conversion of Series B convertible preferred stock to common stock		$ (7,056,421)
Previously Reported [Member] \| Additional Paid in Capital, Common Stock [Member]
Issuance of Series B convertible preferred stock, net of issuance costs				$ 0
Deemed Dividend on Series B convertible preferred stock				(4,782,100)
Conversion of Series B convertible preferred stock to common stock				$ 6,656,442